← Back to screener

Immunovant, Inc. IMVT

Rank #2303 · Nasdaq · $6.0B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
25.2
P/E
-23.1
P/B
16.52
ROE
-71.5%
Op. Margin
–%
Debt Ratio
19%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -23.1x, P/B 16.52x. Ranks in the top 82% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -71.5%. Ranks in the top 92% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 19%. Ranks in the top 13% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2019––$-0.0B$-0.0B–-433
2020––$-0.1B$0.0B–209
2022––$-0.1B$0.1B–22
2023––$-0.2B$0.4B–12
2024––$-0.2B$0.5B–9
2025––$-0.2B$0.5B–10
2026––$-0.3B$0.4B–19

← See the full screener